MARKET

BIVI

BIVI

Biovie Inc
NASDAQ
1.930
+0.020
+1.05%
After Hours: 1.930 0 0.00% 19:30 09/11 EDT
OPEN
1.920
PREV CLOSE
1.910
HIGH
2.020
LOW
1.910
VOLUME
170.76K
TURNOVER
--
52 WEEK HIGH
3.790
52 WEEK LOW
0.8200
MARKET CAP
16.31M
P/E (TTM)
-0.6323
1D
5D
1M
3M
1Y
5Y
1D
BioVie Announces Bezisterim Has Potential To Treat Parkinson's Disease; To Hold Talks With FDA Over Phase 3 Trial Design
Benzinga · 4d ago
Weekly Report: what happened at BIVI last week (0831-0904)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 08/31 17:06
BioVie Doses Final Patient In Phase 2 Trial For Bezisterim In Long COVID; Stock Up
NASDAQ · 08/31 16:50
BioVie completes treatment phase of ADDRESS-LC trial
TipRanks · 08/31 12:10
Weekly Report: what happened at BIVI last week (0824-0828)?
Weekly Report · 08/31 09:30
Weekly Report: what happened at BIVI last week (0817-0821)?
Weekly Report · 08/24 09:30
New to The Street Broadcasts Today Across Bloomberg Television U.S., Latin America and MENA at 6:30 PM ET
Barchart · 08/22 09:40
More
About BIVI
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Webull offers BioVie Inc stock information, including NASDAQ: BIVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIVI stock methods without spending real money on the virtual paper trading platform.